- Home
- INSW vs CGON Comparison
INSW vs CGON Comparison
Compare INSW & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- CGON
- Stock Information
- Founded
- INSW 1999
- CGON 2010
- Country
- INSW United States
- CGON United States
- Employees
- INSW N/A
- CGON N/A
- Industry
- INSW Semiconductors
- CGON
- Sector
- INSW Technology
- CGON
- Exchange
- INSW Nasdaq
- CGON NYSE
- Market Cap
- INSW 1.8B
- CGON 2.0B
- IPO Year
- INSW N/A
- CGON 2024
- Fundamental
- Price
- INSW $41.01
- CGON $26.91
- Analyst Decision
- INSW Buy
- CGON Strong Buy
- Analyst Count
- INSW 2
- CGON 11
- Target Price
- INSW $52.00
- CGON $63.30
- AVG Volume (30 Days)
- INSW 517.1K
- CGON 979.0K
- Earning Date
- INSW 08-06-2025
- CGON 08-07-2025
- Dividend Yield
- INSW 9.73%
- CGON N/A
- EPS Growth
- INSW N/A
- CGON N/A
- EPS
- INSW 6.47
- CGON N/A
- Revenue
- INSW $860,606,000.00
- CGON $662,000.00
- Revenue This Year
- INSW N/A
- CGON N/A
- Revenue Next Year
- INSW $1.88
- CGON $21,843.29
- P/E Ratio
- INSW $6.36
- CGON N/A
- Revenue Growth
- INSW N/A
- CGON 224.51
- 52 Week Low
- INSW $27.20
- CGON $14.80
- 52 Week High
- INSW $56.66
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- INSW 59.51
- CGON 54.12
- Support Level
- INSW $40.35
- CGON $25.14
- Resistance Level
- INSW $40.89
- CGON $27.09
- Average True Range (ATR)
- INSW 1.00
- CGON 1.50
- MACD
- INSW 0.17
- CGON -0.04
- Stochastic Oscillator
- INSW 74.22
- CGON 53.56
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.